Table 1:
Active clinical trials targeting TIM-3, TIGIT, or CD112R
| Target | Agents (manufacturer) | Protocol (tumor types) | Combination agents |
|---|---|---|---|
| TIM-3 | TSR-022, humanized IgG4 (Tesaro) | NCT02817633, phase I (advanced solid tumors) | TSR-023 (anti-PD-1), TSR-033 (anti-LAG-3) |
| NCT03580508, phase II (advanced, localized/unresectable HCC) | TSR-023 (anti-PD-1) | ||
| NCT03307785, phase I (advanced solid tumors) | Niraparib, TSR-042 (anti-PD-1), Bevacizumab (anti-VEGF), platinum-based chemotherapy | ||
| MBG453, humanized IgG4 (Novartis) | NCT02608268, phase I/II (advanced malignancies) | PDR001 (anti-TJ-1) | |
| NCT03066648, phase I (AML or high risk MDS) | Decitabine, PDR001 (anti- PD-1) | ||
| NCT03940352, phase I (AML or high risk MDS) | HDM201, Venetoclax | ||
| NCT03961971, phase I (GBM) | Spartalizumab (anti-PD-1) | ||
| Sym023, human IgG1 (Symphogen) | NCT03489343, phase I (advanced malignancies) | None | |
| NCT03311412, phase I (advanced malignancies) | Sym021 (anti-PD-1), Sym022 (anti-LAG-3) | ||
| LY3321367, human IgG1 (Eli Lilly and Company) | NCT03099109, phase I (advanced relapsed/refractory solid tumors) | LY33000054 (anti-PD-L1) | |
| BGB-A425, humanized IgG1 (BeiGene) | NCT03744468, phase I/II (locally advance solid tumors) | Tislelizumab (anti-PD-1) | |
| RO7121661, bispecific anti-PD-1/TIM-3 (Hoffmann-La Roche) | NCT03099109, phase I (advanced solid tumors) | None | |
| INCAGN02390, IgG1k (Incyte Corporation) | NCT03652077, phase I (advanced malignances) | None | |
| NCT04370704, phase I/II (advanced malignances) | INCMGA00012 (anti-PD-1), INCAGN02385 (anti-LAG-3) | ||
| BMS-986258, (Bristol-Myers Squibb) | NCT03446040, phase I (advanced cancer) | Nivolumab (anti-PD-1), rHuPH20 | |
| SHR-1702 (Jiangsu HengRui) | NCT03708328, phase I (advanced malignances) | Camrelizumab (anti-PD-1) | |
| TIGIT | BMS-986207, human IgG1 (Bristol Myers Squibb) | NCT04150965, phase I/II (multiple myeloma with relapse) | None |
| BGB-A1217, humanized IgG1 (BeiGene) | NCT04047862, phase I/Ib (metastatic solid tumors) | Tislelizumab | |
| Tiragolumab, MTIG7192A, human IgG1 (Genentech) | NCT02794571, phase Ia/b (advanced tumors) | Atezolizumab (anti-PD-L1), carboplatin, cisplatin, pemetrexed, paclitaxel | |
| NCT04045028, phase I (myeloma and lymphoma) | Rituxomab (anti-CD20), Daratumumab/rHuPH20 (anti- CD38/hyaluronidase PH20) | ||
| NCT04045028, phase Ib/II (urothelial carcinoma) | Atezolizumab (anti-PD-L1) | ||
| NCT03281369, phase Ib/II (gastroesophageal cancers) | Atezolizumab (anti-PD-L1) | ||
| NCT03193190, phase Ib/II (pancreatic adenocarcinoma) | Atezolizumab (anti-PD-L1) | ||
| NCT03563716, phase II (lung cancer), | Atezolizumab (anti-PD-L1) | ||
| NCT04294810, phase III (PD-L1 positive non-small lung cancer) | Atezolizumab (anti-PD-L1) | ||
| NCT04300647, phase II (metastatic or recurrent PD-L1 positive cervical cancer) | Atezolizumab (anti-PD-L1) | ||
| NCT04256421, phase III (small cell lung cancer) | Atezolizumab (anti-PD-L1), carboplatin, etoposide | ||
| AB154, humanized IgG1 (Arcus Biosciences) | NCT03628677, phase I (advanced solid malignancies), | Zimberelimab (anti-PD-1) | |
| NCT04262856, phase II (PD-L1 positive non-small lung cancer) | Zimberelimab (anti-PD-1), AB928 (anti-A2a/bR antagonist) | ||
| ASP8374, human IgG4 (Astella Pharma Global Development) | NCT03260322, phase Ib (advanced tumors) | Pembrolizumab (anti-PD-1) | |
| MK-7684, humanied IgG1 (Merck Sharp & Dohme) | NCT4305041, phase I/II (melanoma) | Pembrolizumab (anti-PD-1), MK-1308 (anti-CTLA-4) | |
| NCT04303169, phase I/II (PD-1 refractory melanoma) | Pembrolizumab (anti-PD-1) | ||
| M6223, TIGIT inhibitor (Merck Sharp & Dohme) | NCT04457778, phase I (metastatic solid tumors) | Bintrafusp alfa (anti-PD-L1/TGFβ) | |
| C0M902, TIGIT inhibitor (Compugen) | NCT04354246, phase I (advanced malignancies) | None | |
| CD112R | COM701, inhibitor (Compugen) | NCT03667716, phase I (advanced solid tumors) | Nivolumab (anti-PD-1) |
Antibodies targeting TIM-3 and TIGIT and drugs targeting CD112R found on ClinicalTrials.gov (as of August 2020) that are active in clinical trials for the indicated tumor types and with the combinatorial treatment listed. AML, acute myeloid leukemia; GBM, glioblastoma multiforme; HCC, hepatocellular carcinoma; Ig, immunoglobulin; LAG-3, lymphocyte-activation gene 3 protein; mAb, monoclonal antibody; MDS: myelodysplastic syndrome; PD-1, programmed cell death 1; PD-L1, programmed death ligand 1